Long- and Short-Acting Opioid Addiction Meds Equally Effective Long- and Short-Acting Opioid Addiction Meds Equally Effective
Extended-release naltrexone and buprenorphine/naloxone are similarly efficacious in preventing relapse for patients with opioid use disorder, although naltrexone was more difficult to initiate.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2017 Category: Consumer Health News Tags: Psychiatry News Source Type: news
Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse.
The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone.
Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has doctor...
Source: JEMS Patient Care - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news
Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse.
The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone.
Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has doctor...
Source: JEMS: Journal of Emergency Medical Services News - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news
Opioid Addiction Treatments Face Off in US Trial
CHICAGO (AP) — The first U.S. study to compare two treatments for opioid addiction finds a monthly shot works as well as a daily drug to prevent relapse.
The shot requires days of detox first and that proved to be a stumbling block for many. For those who made it past that hurdle, the shot Vivitrol worked about the same as an older treatment, Suboxone.
Both drugs had high relapse rates and there were overdoses, including fatal ones, in the experiment in 570 adults. The study , published Tuesday in the journal Lancet, is the first to compare the two drugs in the United States, where an opioid addiction epidemic has doctor...
Source: JEMS Patient Care - November 15, 2017 Category: Emergency Medicine Authors: Carla K. Johnson, AP Medical Writer Tags: Patient Care News Source Type: news
Study: Head-to-head comparison of opioid use disorder therapies finds similarities
A study published today in The Lancet found that two different therapies used to treat opioid use disorder – an extended-release naltrexone injection and a combination of buprenorphine and naloxone – have similar outcomes once patients get past the hurdle of starting treatment.
This is the first study to compare the combination therapy and naltrexone head-to-head in the U.S. The study enrolled 570 opioid-dependent adults, 82% of which were using heroin and 16% of which were abusing pain medications.
Get the full story at our sister site, Drug Delivery Business News.
The post Study: Head-to-head comparison of opioid ...
Source: Mass Device - November 15, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Research & Development National Institutes of Health (NIH) Source Type: news
Opioid treatment drugs have similar outcomes once patients initiate treatment
NIDA study compares buprenorphine/naloxone combination to extended release naltrexone. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 14, 2017 Category: American Health Source Type: news
Opioid treatment drugs have similar outcomes once patients initiate treatment
A study comparing the effectiveness of two pharmacologically distinct medications used to treat opioid use disorder – a buprenorphine/naloxone combination and an extended release naltrexone formulation – shows similar outcomes once medication treatment is initiated. Among active opioid users,... (Source: NIDA News)
Source: NIDA News - November 14, 2017 Category: Addiction Tags: Health and Medical Professionals, Heroin, Opioids, Researchers, Treatment Research Source Type: news
Pediatricians ’ Counseling Hopes To End Teen Opioid Addiction Before It Starts
WAREHAM (CBS) – One out of every four teenagers admits to misusing or abusing, a prescription drug.
It’s a dangerous road that can lead to addiction. To prevent and treat drug-use in kids there is now a first-of-its-kind program tackling the issue head-on right at the pediatrician’s office.
At Wareham Pediatrics, the Cat in the Hat welcomes young patients and route markers provide a guide to the exam rooms.
(WBZ-TV)
But the practice itself could be creating a road map to prevent and treat addiction in kids.
(WBZ-TV)
“It was a really helpless feeling to sometimes see kids and families struggling with...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - October 24, 2017 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health Local News Syndicated Local Boston Children's Hospital Confronting The Crisis Lisa Hughes opioid crisis Suboxone Source Type: news
Opioid Blocker as Good as Suboxone in First Head-to-Head Trial (CME/CE)
(MedPage Today) -- Monthly naltrexone (Vivitrol) non-inferior to buprenorphine/naloxone (Source: MedPage Today Pain Management)
Source: MedPage Today Pain Management - October 20, 2017 Category: Anesthesiology Source Type: news
Extended-Release Naltrexone Seems as Effective as Standard Treatment for Opioid Dependence (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD
Injectable extended-release naltrexone (Vivitrol) appears to be as safe and effective as daily oral buprenorphine-naloxone for treating opioid dependence, according to a Norway-based, noninferiority trial … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - October 19, 2017 Category: Primary Care Source Type: news
Guidance Offered for Managing Pain in Patients With Cancer and OUD
For patients with opioid use disorder taking buprenorphine - naloxone, it is deemed appropriate to continue three times - daily dosing (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - October 12, 2017 Category: Psychiatry Tags: Oncology, Pharmacy, Psychiatry, Anesthesiology & amp; Pain, Journal, Source Type: news
Sublingual Buprenorphine/Naloxone Tied to More Adverse Dental Outcomes
More adverse dental outcomes seen with sublingual buprenorphine/naloxone compared with use of transdermal buprenorphine or oral naltrexone (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - October 12, 2017 Category: Psychiatry Tags: Family Medicine, Internal Medicine, Emergency Medicine, Pharmacy, Psychiatry, Journal, Source Type: news
CHMP Backs Two Drugs for Opioid Abuse CHMP Backs Two Drugs for Opioid Abuse
The EMA committee recommends naloxone nasal spray (Nyxoid) for treatment of opioid overdose and buprenorphine plus naloxone sublingual tablets (Zubsolv) for treatment of opioid dependence.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 15, 2017 Category: Consumer Health News Tags: Psychiatry News Alert Source Type: news
Addressing stigma in medication treatment of adolescents with opioid use disorder - Bagley SM, Hadland SE, Carney BL, Saitz R.
: In September 2016, the American Academic of Pediatrics released a policy statement that adolescents with opioid use disorder should be offered pharmacotherapy with buprenorphine/naloxone, methadone, or naltrexone. In our clinical practice, however, we ha... (Source: SafetyLit)
Source: SafetyLit - August 7, 2017 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
Rapid Growth in Medicaid Spending on Medications to Treat Opioid Use Disorder and Overdose (June 2017)
Report used state Medicaid drug utilization files from 2011 to 2016 to assess spending on buprenorphine, naltrexone, and naloxone prescriptions. (Source: HSR Information Central)
Source: HSR Information Central - July 11, 2017 Category: International Medicine & Public Health Source Type: news
